NCT06559345View on ClinicalTrials.gov

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL

PHASE2RecruitingINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

March 17, 2025

Primary Completion Date

July 31, 2029

Study Completion Date

August 31, 2029

Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
RADIATION

TMLI

The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.

RADIATION

TBI

The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.

DRUG

Cyclophosphamide

The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.

Trial Locations (1)

450001

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Zhengzhou University

OTHER